Story

Blackstone Explores Sale of ZO Skin Health at Potential $2 Billion Valuation, Sources Say

ENTHMSVIIDZHZH-TWJAKOHI
Sep 8, 20261 min read
Blackstone Explores Sale of ZO Skin Health at Potential $2 Billion Valuation, Sources Say
Text size
Background

Private equity firm Blackstone Inc. is exploring a sale of the medical-grade skincare company ZO Skin Health, a transaction that could value the brand at approximately $2 billion, according to people familiar with the matter.

The Potential Deal

Blackstone is working with investment bankers from Citigroup and Raymond James to manage the sale process, the sources said. The discussions are reportedly in an early stage, and the sources requested anonymity to discuss private information.

When reached for comment, Blackstone and Citigroup declined to comment on the matter. ZO Skin Health and Raymond James did not immediately respond to requests for comment, according to the original report from Reuters.

Market Context

Sample IUX Markets – In-articleAd

The potential sale comes at a time of high interest from strategic buyers in the premium skincare market. Brands like ZO, which are distributed through physicians and other skincare professionals, are seen as particularly attractive.

Investors often favor these clinically backed brands over their over-the-counter counterparts due to their perceived higher efficacy and more stable consumer demand. This distribution model can create a loyal customer base that relies on professional recommendations.

About ZO Skin Health

Founded in 2007 by dermatologist Dr. Zein Obagi, ZO Skin Health offers a range of therapeutic skincare products, including cleansers, serums, and toners. The company has established a strong presence in the professional channel, selling its products exclusively through authorized medical practices and skincare specialists.

Read next

More on Stocks
Back to latest news

LATEST